ReviewInternational journal of molecular sciences2023
Benefits of Biotics for Cardiovascular Diseases.
Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 18 citations in OpenAlex.
- Bifidobacterium pseudolongum TISTR 2737 Supplementation Alleviates High Fructose-Induced Vascular Injury and Inflammation by Modulating eNOS Uncoupling, AGEs/RAGE Pathway, and NADPH Oxidase Expression.Probiotics and antimicrobial proteins · 2026Article
- Gut Microbiota as an Innovative Therapeutic Target in Cardiovascular Diseases from a Metabolic and Inflammatory Perspective.Biomedicines · 2026Review
- Review
- Scaling Up Postbiotics Production: A Prospective Review of Processes and Health Benefits.Probiotics and antimicrobial proteins · 2026Review
- Gut microbiota dysbiosis and the gut-lung axis in COPD: mechanisms, clinical relevance, and microbiota-targeted interventions.Frontiers in cell and developmental biology · 2026Review
- Gender-specific protective effects of dietary index for gut microbiota on cardiovascular disease: insights from NHANES 2007-2020.BMC cardiovascular disorders · 2025Article
- The Hypolipemic Properties of Kaempferol Presented in Microwaved Cooked Broccoli Between Hyperlipidemic Rat Models.Food science & nutrition · 2025Article
- Relationship between depression and oral microbiome diversity: analysis of NHANES data (2009-2012).BMC oral health · 2025Article
- Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines.Signal transduction and targeted therapy · 2025Review
- Mushroom and Kefir Functional Characterizations: Hypolipidemia and Gut Microbiota Modulations in Rat Models.Food science & nutrition · 2024Article
- Gut microbiota: Implications in pathogenesis and therapy to cardiovascular disease (Review).Experimental and therapeutic medicine · 2024Review
- Article
- The potential preventive effect of probiotics, prebiotics, and synbiotics on cardiovascular risk factors through modulation of gut microbiota: A review.Food science & nutrition · 2024Review
- Next-Generation Probiotics as Novel Therapeutics for Improving Human Health: Current Trends and Future Perspectives.Microorganisms · 2024Review
- Mechanisms of inflammatory microenvironment formation in cardiometabolic diseases: molecular and cellular perspectives.Frontiers in cardiovascular medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases are the main cause of death in many countries, and the better prevention and prediction of these diseases would be of great importance for individuals and society. Nutrition, the gut microbiota, and metabolism have raised much interest in the field of cardiovascular disease research in the search for the main mechanisms that promote cardiovascular diseases. Understanding the interactions between dietary nutrient intake and the gut microbiota-mediated metabolism may provide clinical insight in order to identify individuals at risk of cardiometabolic disease progression, as well as other potential therapeutic targets to mitigate the risk of cardiometabolic disease progression. The development of cardiometabolic diseases can be modulated by specific beneficial metabolites derived from bacteria. Therefore, it is very important to investigate the impact of these metabolites on human health and the possibilities of modulating their production with dietary supplements called biotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.